Safety, Pharmacokinetics, and Efficacy Study of Porcine and Rabbit Antithymocyte Globulin in the Treatment of Patients With Severe Aplastic Anemia: A Multicenter, Prospective, Randomized, Open‐Label Clinical Trial

Yawen Zhang, Yingying Zhang, Yuemin Gong, Yu Sun, Guangsheng He · 2026

Read Safety, Pharmacokinetics, and Efficacy Study of Porcine and Rabbit Antithymocyte Globulin in the Treatment of Patients With Severe Aplastic Anemia: A Multicenter, Prospective, Randomized, Open‐Label Clinical Trial by Yawen Zhang, Yingying Zhang, Yuemin Gong, Yu Sun, Guangsheng He (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13676421.txt.

Description

Yawen Zhang and co-authors ran a head-to-head trial in 2026 of two immune drugs for a grave marrow failure. In severe aplastic anemia, the body's own T cells drain the marrow of blood-making cells. Both drugs are serums that cull T cells, one from pigs and one from rabbits, and they are the sole picks in mainland China. Ninety-three patients who could not get a transplant joined at many centers from 2020 to 2024.

Both drugs peaked in the blood on day five, but the rabbit form cleared faster. Early white cell paths split between the groups, then met again at one month. At six months and two years, response and survival rates were much the same. Infection and serum sickness rates also matched. The team backs either drug as a first pick.

Catalog record

CREATORYawen Zhang, Yingying Zhang, Yuemin Gong, Yu Sun, Guangsheng He
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE29 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13676421

Browse the full library · About the Tower of Babel